Dawnrays Pharma is a Hong Kong-based pharmaceutical group, established in 1995 with the main operations in Suzhou, Jiangsu Province. Since July 2003, Dawnrays Pharma has been listed on the Main Board of Hong Kong Stock Exchange. Dawnrays Pharma owns nine subsidiaries, namely Dawnrays International Company Limited, Dawnrays International Co., Ltd., Dawnrays Biotechnology Capital (Asia) Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Suzhou Dawnrays Pharmaceutical Science and Technology Co., Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd., Ltd., Dawnrays Pharma (Hong Kong) Limited, Fujian Dawnrays Pharmaceutical Co., Ltd., and Lanzhou Dawnrays Pharmaceutical Co., Ltd.

The Group is engaged in the development, manufacturing and the sale of cephalosporin antibiotics, and various system specific medicines (generic drugs). The product range also covers various drug formulations, including bulk medicine, powder for injection, tablets, capsules, granules and intermediates. It is one of the few third generation cephalosporin manufacturers in China that adopts a comprehensive vertically integrated production process. Dawnrays Pharma is equipped with advanced production process and techniques, especially its well-known advanced technology of solvent crystallization. In terms of our costs control, technologies capabilities, sales and distribution network, products qualities and the product prices, Dawnrays Pharma is more competent than all other enterprises in the industry. Dawnrays Pharma has establised sucessfully leading product brands with high market shares in the areas of 3rd generation cephalosporin products, cardiovascular system, anti-hepatitis B virus and anti-allergy drugs etc., such as Dawnrays™ brand API, powder for injections drug in "Xian" series of medicines, anti-hypertensive drug in "An" series of medicines, Rallyado™ and Cecoride™, of which Amlozen™ and Cecoride™ are the first generics in China.

At present, workshops of sterile bulk drugs, powder for Injection (cephalosporins) and solid dosage forms of Dawnrays Pharma have all passed the latest Chinese GMP inspection and gained the certification.

Dawnrays Pharma develops high-quality drugs that can save patients' treatment costs to meet future basic market requirements, and become a leader in some areas in China and even the world.